Although Staphylococcus aureus is a prominent cause of infections, no vaccine is currently available. Active vaccination relies on immune memory, a core competence of the adaptive immune system. To elucidate whether adaptive immunity can provide protection from serious complications of S. aureus infection, a prospective observational study of 44 patients with S. aureus infection complicated by bacteremia was conducted. At diagnosis, serum IgG binding to S. aureus extracellular proteins was quantified on immunoblots and with Luminex-based FLEXMAP 3D™ assays comprising 64 recombinant S. aureus proteins. Results were correlated with the course of the infection with sepsis as the main outcome variable. S. aureus-specific serum IgG levels at diagnosis of S. aureus infection were lower in patients developing sepsis than in patients without sepsis (P b 0.05). The pattern of IgG binding to eight selected S. aureus proteins correctly predicted the disease course in 75% of patients. Robust immune memory of S. aureus was associated with protection from serious complications of bacterial invasion. Serum IgG binding to eight conserved S. aureus proteins enabled stratification of patients with high and low risk of sepsis early in the course of S. aureus infections complicated by bacteremia. Significance: S. aureus is a dangerous pathogen of ever increasing importance both in hospitals and in the community. Due to the crisis of antibiotic resistance, an urgent need exists for new strategies to combat S. aureus infections, such as vaccination. To date, however, all vaccine trials have failed in clinical studies. It is therefore unclear whether the adaptive immune system is at all able to control S. aureus in humans. The paper demonstrates the use of proteomics for providing an answer to this crucial question. It describes novel results of a prospective study in patients with S. aureus infection complicated by bloodstream invasion. Immune proteomic analysis shows that robust immune memory of S. aureus -reflected by strong serum IgG antibody binding to S. aureus antigens -is associated with clinical protection from sepsis. This lends support to the notion of a vaccine to protect against the most serious complications of S. aureus infection. Hence, the data encourage further efforts in vaccine development.
bacterial invasion, since carriers have an increased risk of S. aureus infection mostly with their colonizing strain [1, 8] .
However, there are indications that the adaptive immune system may confer clinical protection against severe S. aureus infection. First, S. aureus bloodstream infection has a better outcome in carriers than in non-carriers, which could be due to the generation of strain-specific immune memory during colonization [9, 10] . Moreover, functional defects of adaptive immunity increase the risk of severe S. aureus infection in humans and animal models. The Th17 T cell subpopulation is currently receiving much attention in this context [11] [12] [13] [14] [15] . Finally, good protection has been achieved in animal models with active and passive vaccines targeting a variety of S. aureus proteins [16, 17] .
The natural human antibody response to S. aureus is characterized by pronounced heterogeneity [6, 18] , reflecting the immune memory formed during an individual's encounters with S. aureus. We hypothesized that upon bacterial invasion, immune memory of S. aureus will confer clinical protection, and the S. aureus-specific antibody response might permit patient stratification. To test this hypothesis, we conducted a prospective observational study with 44 patients diagnosed with S. aureus infection complicated by bacteremia.
Patients, materials and methods

Clinical study design
In a prospective observational study, sera from a convenience sample of patients with S. aureus infection complicated by bacteremia were collected at diagnosis as previously described [19] . Human experimentation guidelines of the United States Department of Health and Human Services and those of the authors' institution(s) were followed while performing of clinical research. The study was approved by the University of Maryland Baltimore Institutional Review Board and was granted a waiver of informed consent. Patients with AIDS, severe immune suppression other than AIDS and symptoms of infection more than 4 days prior to infection presentation were excluded. Patients were monitored for three days after the first positive blood culture for the presence or development of sepsis. The outcome criteria for uncomplicated sepsis, severe sepsis and septic shock were adapted from the American College of Chest Physicians and Society for Critical Care Medicine definition [20] . Other variables shown in Table 1 were abstracted from the medical record.
S. aureus isolates, protein extracts and bacterial cell preparations
Infecting S. aureus isolates were molecularly typed based on their spa-sequences, and virulence genes encoding superantigens, exfoliative toxins, as well as PVL were identified by multiplex-PCR [21] . Extracellular protein extracts were obtained from a protein A gene (spa) deletion mutant of S. aureus USA300 (USA300Δspa) cultivated to stationary phase under iron-restricted conditions [22] . Whole bacterial cells were washed and UV-inactivated. Recombinant S. aureus proteins were obtained from Protagen AG (Dortmund, Germany).
Quantification of serum IgG binding to S. aureus
Serum IgG binding to extracellular bacterial protein extracts was quantified by semi-automated immunoblotting (Peggy Simple Western Assay). Binding to the S. aureus cell surface was determined by ELISA. Finally, serum IgG specific to 64 recombinant S. aureus proteins was measured using FLEXMAP 3D™ technology, and normalized mean fluorescent intensities were calculated as measures of antibody binding intensity.
Data analysis and statistics
Binding data obtained with immunoblot or ELISA were compared using the Mann-Whitney test (two groups) or the Kruskal-Wallis test with Dunn's post-test (more than two groups). P-values below 0.05 were considered statistically significant. Principle component analysis (PCA), partial least square analysis (PLS) and prediction analysis of the FLEXMAP 3D™ data were performed using the Analyst Software (Genedata, Basel, Switzerland).
The supporting information contains additional details about patients, materials and methods.
Results
Infecting S. aureus isolates
Of the 44 infecting S. aureus isolates, 14 (35%) belonged to the spa type t008 and most of these were further characterized by agr type 1, pvl and the superantigen gene seq, indicating that these strains represent USA300 strains. The remaining isolates were of mixed spa types or could not be clustered. None of the isolates were positive for the exfoliative toxins encoding genes eta or etd (Table S1 ).
Serum IgG binding to S. aureus cells or extracellular proteins
USA300, the most frequent cause of bloodstream invasion in this cohort, was selected for quantification of S. aureus-specific serum IgG. A protein-A gene deletion mutant, USA300Δspa, was generated to avoid non-specific antibody binding. Patient sera were obtained at diagnosis, no later than four days after onset of symptoms, and IgG binding to extracellular bacterial proteins was measured (n = 46). Total IgG binding varied by a factor of 27 (range: 65140-1763988 AUC, Fig. 1A) . Patients who subsequently developed sepsis -uncomplicated sepsis, severe sepsis or septic shock -showed lower IgG binding to S. aureus extracellular proteins (P = 0.0481, Fig. 1B) . Moreover, IgG binding to extracellular S. aureus proteins decreased with increasing sepsis severity (Fig. 1D) . On the other hand, 7 out of 11 patients in the lower quartile of the antibody binding values developed sepsis, but only 3 out of 11 in the upper quartile did so (Fig. 1E) . Similarly, IgG binding to the bacterial surface was lower in the sepsis group than in patients who remained sepsis-free (P = 0.0409, Fig. 1C ).
Serum IgG binding to selected S. aureus proteins
To identify antibody specificities associated with protection against sepsis, IgG binding to 64 recombinant S. aureus proteins was measured, comprising extra-cellular, surface bound and cytoplasmic S. aureus proteins (Table S2) . 44 sera were available for this analysis (sera obtained before or at onset of symptoms). At first, patients were grouped into (i) no sepsis, (ii) uncomplicated sepsis, and (iii) severe sepsis or septic shock and results were subjected to a partial least squares analysis (PLS) (Fig. 2A) . Patients with uncomplicated sepsis and severe sepsis/ septic shock clustered together in one area and were hence handled as one group, "sepsis", in a second PLS analysis. This resulted in a separation from patients without sepsis, as shown in Fig. 2B .
The top 20 S. aureus proteins responsible for the discrimination are listed in Table 2 . Almost all of these proteins belonged to the extracellular proteome, which elicited the strongest antibody binding, as expected (Fig. 3) . They included known toxins and virulence factors of S. aureus and also proteins of unknown function. Further analysis with a support vector machine revealed the best discrimination between patients with and without sepsis by applying Fisher linear discriminant analysis to the intensities of IgG binding to the top 8 proteins: phospholipase C (Plc), staphopain B (SspB), the immunodominant staphylococcal protein A (IsaA), the staphylococcal exotoxin M (SEM), glycerophosphoryl diester phophodiesterase (GlpQ), the C component of γ-hemolysin (HlgC) and two proteins of unknown function, SACOL0444 and SACOL0985. To validate this result, a principal component analysis was performed with serum IgG binding to the top 8 proteins upon diagnosis. The degree of separation of patients with and without subsequent sepsis is depicted in Fig. 2C . Sepsis was correctly predicted by Fisher linear discriminant analysis in 16 of 21 cases and no sepsis in 17 out of 23 cases; thus, the prediction was correct in 75% of the cases (sensitivity 76%; specificity 74%). IgG binding to the top 8 proteins differed significantly between patients who subsequently developed sepsis or no sepsis as depicted in Fig. 2D . However, the two groups could not be separated on the basis of antibody binding to single S. aureus proteins.
Details of the data analysis are provided in the supporting material.
Discussion
At diagnosis of S. aureus bloodstream infection, serum IgG binding to the bacterial extracellular proteome was inversely correlated with the risk of sepsis development. We observed an almost 30-fold variation in total serum IgG binding to extracellular S. aureus proteins. Very high S. aureus-specific IgG serum levels characterized a subgroup of patients who almost never experienced sepsis. The fate of patients with medium to low intensity IgG binding was non-uniform. Antibody binding to extracellular S. aureus proteins and S. aureus cells discriminated both groups equally well.
An immune proteome signature of eight S. aureus proteins predicted the disease course of bacteremia patients with 75% accuracy (76% sensitivity and 74% specificity). This proteomic signature was mainly comprised of conserved extracellular S. aureus proteins: with the exception of the superantigen SEM, all belong to the S. aureus core genome [23] . This was expected because patients were not stratified according to the type of the infecting S. aureus isolate, and many S. aureus toxin genes -such as those encoding superantigens and other toxins -are highly variable in the species S. aureus, as are serum antibodies specific to them [10, 24] . Keeping in mind that the infecting S. aureus isolates in the present study reflect the epidemiological situation in the US, the results should be regarded as a proof of concept. While the predictive value of the described S. aureus signature antigens may not justify clinical application, the results do provide impetus for the investigation of larger patient cohorts from different geographical areas to either define a universal immune proteome signature of protection against S. aureus sepsis or to develop more specialized tests capturing the antigen repertoire of invasive S. aureus in different regions of the world.
Although vaccine trials have not prevented S. aureus infection [4, 5, 25] , the results of this prospective study strengthen the case of a protective role of the adaptive immune system in ameliorating S. aureus infections. Specific serum IgG indicates immune memory of S. aureus, a core competence of the adaptive immune system, which is the basis of vaccination effects. It was clearly associated with protection from septic complications of S. aureus bloodstream invasion. Remarkably, the association of S. aureus-specific serum IgG with a favorable disease course was lost if sera were obtained later than 4 days after infection presentation (data not shown). This suggests that the protection from septic complications of S. aureus invasion was mainly provided by pre-existing specific IgG or immune memory of S. aureus rather than by the IgG response triggered by the current infection.
The findings corroborate previous observations: S. aureus carriers have higher levels of specific antibodies than do non-carriers [6, 18] , but a lower mortality rate in the case of S. aureus bacteremia [9] . Similarly, patients with uncomplicated recovery from bloodstream infection had higher antibody titers specific to S. aureus exotoxins at diagnosis than did patients who developed sepsis [19] . Epidermolysis bullosa Fig. 2 . Stratification of patients according to disease progression (sepsis or uncomplicated recovery) based on S. aureus-specific antibodies. Quantification of IgG specific to 64 S. aureus proteins was performed with FLEXMAP 3D™ technology. Patients with uncomplicated sepsis and severe sepsis or septic shock grouped together (as sepsis) in partial least squares analysis (PLS) (A). PLS showed good separation of patients with sepsis -including uncomplicated sepsis, severe sepsis and septic shock -from patients with no sepsis (B). Using the eight most discriminating S. aureus proteins for a principal component analysis (see also Table 2 ) enabled stratification of septic and non-septic patients at diagnosis of S. aureus bloodstream invasion (C). Differences of quantified median IgG binding to these eight proteins between septic and non-septic patients are shown in D.
patients, suffering from chronic wounds heavily colonized by S. aureus, show high serum concentrations of anti-staphylococcal antibodies and do not usually develop systemic S. aureus infection [26] . Conversely, children with low pre-existing IgG titers to S. aureus α-hemolysin and Panton-Valentine leukocidin were more prone to invasive S. aureus disease [27] . In summary, the literature agrees about a negative correlation between specific antibodies and severity of S. aureus disease.
The present work extends this knowledge and indicates for the first time that patient stratification based on S. aureus-specific antibodies may be possible at diagnosis of S. aureus bloodstream invasion. In particular, a subgroup of bacteremia patients with very strong S. aureus-specific antibody binding rarely developed septic complications. Such information may also be useful in clinical intervention studies, such as active or passive S. aureus vaccination trials. For this, a panel of eight S. aureus antigens identified among 64 tested recombinant S. aureus antigens was instrumental. Encouragingly -in contrast to earlier data reported from the same patient cohort [19] -seven of these eight signature proteins belong to the conserved S. aureus core genome. This made it unnecessary to filter patients according to the infecting S. aureus strain and will make it easier to translate the findings into a diagnostic tool.
Regarding the mechanisms of protection provided by the adaptive immune system, there are several mutually non-exclusive possibilities [28] . On the one hand, antibodies may opsonize the bacteria or neutralize potent S. aureus virulence factors such as the pore-forming toxins α-toxin, PVL and LukE/LukF, as well as superantigens. On the other hand, the antibodies might also be considered as a marker of S. aureusspecific T cell memory, because most B cells require cognate (antigenspecific) T cell help to generate antibodies, especially for performing a class switch from IgM to other Ig subclasses. Besides help for B cells, memory T cells could fulfill numerous functions in anti-bacterial defense, e.g., they promote the maturation of neutrophils, their release from the bone marrow and recruitment to the site of infection [28] [29] [30] .
In summary, besides indicating the possibility of patient stratification according to their sepsis risk, our data lend support to the idea of a vaccine to protect against the most serious complications of S. aureus infection and encourage further efforts in this direction.
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